

Letter to the editor: A genetic-based algorithm for personalized resistance training

Type:

Review / Comment / Letter to Editors

Keywords:

Genetic polymorphism, Personalized training, athletes, Talent Identification, athletic performance

1 Letter to the editor: A genetic-based algorithm for personalized resistance training

2 Abstract

3 In a recent paper entitled “A genetic-based algorithm for personalized resistance training”,
4 Jones et al. [1] presented an algorithm of 15 performance-associated gene polymorphisms that
5 they propose can determine an athlete’s training response by predicting power and endurance
6 potential. However, from the design of their studies and the data provided, there is no
7 evidence to support these authors’ assertions. Progress towards such a significant
8 development in the field of sport and exercise genomics will require a paradigm shift in line
9 with recent recommendations for international collaborations such as the Athlome Project
10 (see www.athlomeconsortium.org). Large-scale initiatives, involving numerous multi-centre
11 and well-phenotyped exercise training and elite performance cohorts, will be necessary before
12 attempting to derive and replicate training and/or performance algorithms.

13 Comment

14 In a recent paper entitled “A genetic-based algorithm for personalized resistance training”,
15 Jones et al. [1] proposed an algorithm of 15 performance-associated gene polymorphisms that
16 they assert can determine an athlete’s training response by predicting power and endurance
17 potential. Two studies were conducted and involved athletes from several sports (e.g.
18 swimming, ski/snowboard, squash, motorsport, and football players) undergoing an eight-
19 week high- or low-intensity resistance training intervention comprising of one or two training
20 sessions per week; participants continued sport-specific training and competition during the
21 intervention period. The DNAFit Peak Performance Algorithm™ was used to calculate
22 percentage power/endurance score ratio using the 15 gene polymorphisms. Briefly, this
23 involved the summation of assigning a point from 0-4, depending on the putative effect of

24 each allele on power and/or endurance performance. Based on this derived power/endurance
25 score, subjects were assigned to either an endurance or power genotype training group
26 involving low-intensity or high-intensity resistance training, respectively. The only
27 associations reported were between 5 of the 15 gene polymorphisms and training response as
28 assessed by a countermovement jump (CMJ) and an aerobic-3 min cycle test (Aero3)
29 determined before and after the intervention; albeit none of these associations reached
30 statistical significance. The authors also reported an increase in CMJ and Aero3 performance
31 when assessed within each of the two training groups. On the basis of these results, the
32 authors concluded that the DNAFit Peak Performance AlgorithmTM can be used for
33 personalised resistance-training prescription.

34 It is clear from the study design and the data provided by Jones et al. that there is no evidence
35 to support these authors' assertions. The DNAFit Peak Performance AlgorithmTM used by
36 these authors comprises 15 polymorphisms in 14 genes (*ACE*, *ACTN3*, *ADRB2*, *AGT*,
37 *BDKRB2*, *COL5A1*, *CRP*, *GABPB1*, *IL6*, *PPARA*, *PPARGCIA*, *TRHR*, *VDR* and *VEGFA*);
38 most of which have been associated, albeit tentatively with sports performance in the
39 literature (see Table 1 and [2]). To our knowledge, there is no direct evidence linking *CRP*
40 (rs1205) polymorphism to endurance performance (not included in Table 1); this specific
41 polymorphism has recently been linked to a protective effect in the pathogenesis of
42 cardiovascular heart disease in a meta-analysis [3]. The 15 gene polymorphisms have been
43 "identified" primarily using the candidate gene approach and applied to cohorts with small
44 sample sizes [4, 5]. As presented in Table 1, there are positive and negative findings for some
45 genetic markers but few of these polymorphisms have been replicated. Notably, for the *TRHR*
46 gene variant, there is only one study supporting the link with lean body mass variation [6, 7]
47 in 1000 US whites after several replication attempts in three different cohorts consisting of in
48 total over 6000 white US and Chinese participants. The Vitamin D receptor *BsmI* (rs1544410)

49 polymorphism has also been associated with muscle strength in elderly population in three
50 studies but results remain inconclusive [8]. In contrast, *ACE* I/D and *ACTN3* R577X have
51 been extensively studied and replicated to some degree in different populations [9], these two
52 polymorphisms (together, separately, or part of an algorithm) do not predict training response
53 [2, 10, 11].

54 It is widely acknowledged that a single gene or a combination of a few genes (using genotype
55 score) may explain a very low percentage of sports performance variation, for example, a 2-
56 3% of sprinting performance variability may be explained by *ACTN3* genotype [11, 12].
57 Nevertheless, a recent meta-analysis of genome-wide association studies and their replications
58 reported that common genetic variants could not discriminate elite endurance athletes from
59 respective control populations (GENATHLETE, Japan, Australia, Poland, Russia, Spain,
60 Kenya, and Ethiopia) [13]. Therefore, the research evidence to date to support the selection of
61 any polymorphism is weak [11, 14, 15]. Timmons et al. and Bouchard et al. were the first to
62 investigate training response using genome-wide exploration. Timmons et al. reported a
63 discovery of 29 transcripts that predicted maximum oxygen uptake ($\dot{V}O_2\text{max}$) training
64 response, and these transcripts contained 11 single-nucleotide polymorphisms (SNPs)
65 explaining 23% of the variance in gains in $\dot{V}O_2\text{max}$ [16]. Bouchard et al. used data from the
66 HERITAGE study (Health, Risk factors, Training and Genetics) and identified a set of 21
67 SNPs accounting for 49% of the variance in $\dot{V}O_2\text{max}$ trainability [17]. However, none of the
68 training-associated SNPs reported by Timmons et al. [16] were replicated by Bouchard et al.
69 [17], nor were any of the “putative” training-associated SNPs reported in either study used in
70 the DNAfit Peak Performance Algorithm™. The study by Jones et al. also highlights a
71 number of methodological problems typically associated with the sport and exercise genomics
72 literature [18] such as small sample size, sports variation and low number of training sessions.
73 For example, both experiments in the Jones et al. employed very small sample sizes of 28 and

74 39 participants, respectively. Although authors stated that the sample sizes used were
75 sufficient after power calculation, details of the power calculation were not provided and is
76 most unlikely given the data presented and on the basis of other studies [19-21]. Progress
77 towards developing training and/or performance algorithms will require a paradigm shift in
78 line with recent recommendations for international collaborations [22] such as the Athlome
79 Project (see www.athlomeconsortium.org). Such large-scale initiatives, designed specifically
80 to overcome many of the limitations of small single-site studies will be necessary before
81 attempting to derive and replicate training and performance algorithms.

82 In conclusion, while it is widely acknowledged that a favourable genotype combined with
83 suitable training will enhance trainability and sporting performance, to date few (i.e. *ACTN3*
84 and *ACE*) polymorphisms have been associated with an acceptable level of replication with
85 endurance or power athletic performance, and none of these associations are strong enough to
86 predict elite sports performance or trainability [14, 23, 24]. Currently, there is lack of
87 scientific evidence supporting the predictive values of genetic tests (direct-to-consumer) for
88 prescription of exercise training programmes, or for that matter, talent identification. Further
89 studies with replication are needed in order for genetic variants to be used in personalised
90 training prescription. As stated by Webborn et al., research findings should not be
91 misinterpreted for commercial purposes. Jones et al. [1] are premature in their attempt to
92 demonstrate that a genetic test using DNAfit Peak Algorithm™ can determine the training
93 response by predicting power and endurance potential. There are important limitations in their
94 study design and interpretation of their results. Their suggestion of using a somewhat
95 ambiguous algorithm to prescribe individualised training is premature. While acknowledging
96 the difficulties in translating research discoveries, it is the responsibility of researchers to be
97 cautious and not to over-interpret their research findings as this can motivate unsubstantiated
98 commercial exploitation. Sarzynski et al. recently developed a framework for translating

99 research discoveries that included useful information on sample size requirements and
100 preferred technologies for discovery and replication phases of genetic research with particular
101 reference to exercise genomics[25].

102 References

- 103 1. Jones N KJ, Suraci B, Collins DJ, de Lorenzo D, Pickering C, Grimaldi KA. A
104 genetic-based algorithm for personalized resistance training. *Biol Sport*. 2016;33(2):117-26.
 - 105 2. Wang G, Padmanabhan S, Wolfarth B, Fuku N, Lucia A, Ahmetov, II, Cieszczyk P,
106 Collins M, Eynon N, Klissouras V, Williams A, Pitsiladis Y. Genomics of elite sporting
107 performance: what little we know and necessary advances. *Advances in genetics*.
108 2013;84:123-49.
 - 109 3. Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, Baños-González MA, Torres-
110 Hernández ME, López-Narváez ML, Yañez-Rivera TG, González-Castro TB. The role of
111 gene variants of the inflammatory markers CRP and TNF- α in cardiovascular heart disease:
112 systematic review and meta-analysis. *Int J Clin Exp Med*. 2015;8(8):11958-84.
 - 113 4. Pitsiladis Y, Wang G, Wolfarth B, Scott R, Fuku N, Mikami E, He Z, Fiuza-Luces C,
114 Eynon N, Lucia A. Genomics of elite sporting performance: what little we know and
115 necessary advances. *British journal of sports medicine*. 2013;47(9):550-5.
 - 116 5. Tanaka M, Wang G, Pitsiladis YP. Advancing sports and exercise genomics: moving
117 from hypothesis-driven single study approaches to large multi-omics collaborative science.
118 *Physiological genomics*. 2016;48(3):173-4.
 - 119 6. Roth SM. Genetic aspects of skeletal muscle strength and mass with relevance to
120 sarcopenia. *Bonekey Rep*. 2012;1:58.
-

-
- 121 7. Liu XG, Tan LJ, Lei SF, Liu YJ, Shen H, Wang L, Yan H, Guo YF, Xiong DH, Chen
122 XD, Pan F, Yang TL, Zhang YP, Guo Y, Tang NL, Zhu XZ, Deng HY, Levy S, Recker RR,
123 Papasian CJ, Deng HW. Genome-wide association and replication studies identified TRHR as
124 an important gene for lean body mass. *Am J Hum Genet.* 2009;84(3):418-23.
- 125 8. Garatachea N, Lucia A. Genes and the ageing muscle: a review on genetic association
126 studies. *Age (Dordr).* 2013;35(1):207-33.
- 127 9. Ma F, Yang Y, Li X, Zhou F, Gao C, Li M, Gao L. The association of sport
128 performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-
129 analysis. *PloS one.* 2013;8(1):e54685.
- 130 10. Guth LM, Roth SM. Genetic influence on athletic performance. *Current opinion in*
131 *pediatrics.* 2013;25(6):653-8.
- 132 11. Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, Ashley
133 E, Byrne N, Camporesi S, Collins M, Dijkstra P, Eynon N, Fuku N, Garton FC, Hoppe N,
134 Holm S, Kaye J, Klissouras V, Lucia A, Maase K, Moran C, North KN, Pigozzi F, Wang G.
135 Direct-to-consumer genetic testing for predicting sports performance and talent identification:
136 Consensus statement. *British journal of sports medicine.* 2015;49(23):1486-91.
- 137 12. Moran CN, Yang N, Bailey ME, Tsiokanos A, Jamurtas A, MacArthur DG, North K,
138 Pitsiladis YP, Wilson RH. Association analysis of the ACTN3 R577X polymorphism and
139 complex quantitative body composition and performance phenotypes in adolescent Greeks.
140 *Eur J Hum Genet.* 2007;15(1):88-93.
- 141 13. Rankinen T, Fuku N, Wolfarth B, Wang G, Sarzynski MA, Alexeev DG, Ahmetov, II,
142 Boulay MR, Cieszczyk P, Eynon N, Filipenko ML, Garton FC, Generozov EV, Govorun VM,
143 Houweling PJ, Kawahara T, Kostyukova ES, Kulemin NA, Larin AK, Maciejewska-
144 Karlowska A, Miyachi M, Muniesa CA, Murakami H, Ospanova EA, Padmanabhan S,
145 Pavlenko AV, Pyankova ON, Santiago C, Sawczuk M, Scott RA, Uyba VV, Yvert T, Perusse
-

-
- 146 L, Ghosh S, Rauramaa R, North KN, Lucia A, Pitsiladis Y, Bouchard C. No Evidence of a
147 Common DNA Variant Profile Specific to World Class Endurance Athletes. *PLoS one*.
148 2016;11(1):e0147330.
- 149 14. Camporesi S, McNamee MJ. Ethics, genetic testing, and athletic talent: children's best
150 interests, and the right to an open (athletic) future. *Physiological genomics*. 2016;48(3):191-5.
- 151 15. Eynon N, Hanson ED, Lucia A, Houweling PJ, Garton F, North KN, Bishop DJ.
152 Genes for elite power and sprint performance: ACTN3 leads the way. *Sports medicine*.
153 2013;43(9):803-17.
- 154 16. Timmons JA, Knudsen S, Rankinen T, Koch LG, Sarzynski M, Jensen T, Keller P,
155 Scheele C, Vollaard NB, Nielsen S, Akerstrom T, MacDougald OA, Jansson E, Greenhaff PL,
156 Tarnopolsky MA, van Loon LJ, Pedersen BK, Sundberg CJ, Wahlestedt C, Britton SL,
157 Bouchard C. Using molecular classification to predict gains in maximal aerobic capacity
158 following endurance exercise training in humans. *Journal of applied physiology*.
159 2010;108(6):1487-96.
- 160 17. Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, Sung YJ, Rao DC,
161 Rankinen T. Genomic predictors of the maximal O₂ uptake response to standardized
162 exercise training programs. *Journal of applied physiology*. 2011;110(5):1160-70.
- 163 18. Pitsiladis Y, Wang G. Necessary advances in exercise genomics and likely pitfalls.
164 *Journal of applied physiology*. 2011;110(5):1150-1.
- 165 19. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex
166 genetic traits: practical considerations. *Nature reviews Genetics*. 2002;3(5):391-7.
- 167 20. Long AD, Langley CH. The power of association studies to detect the contribution of
168 candidate genetic loci to variation in complex traits. *Genome research*. 1999;9(8):720-31.
- 169 21. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. *American*
170 *journal of hypertension*. 2002;15(2 Pt 1):201-5.
-

-
- 171 22. Bouchard C. Exercise genomics-a paradigm shift is needed: a commentary. British
172 journal of sports medicine. 2015;49(23):1492-6.
- 173 23. Collins M, September AV, Posthumus M. Biological variation in musculoskeletal
174 injuries: current knowledge, future research and practical implications. British journal of
175 sports medicine. 2015;49(23):1497-503.
- 176 24. Mattsson CM, Wheeler MT, Waggott D, Caleshu C, Ashley EA. Sports genetics
177 moving forward: lessons learned from medical research. Physiological genomics.
178 2016;48(3):175-82.
- 179 25. Sarzynski MA, Loos RJ, Lucia A, Pérusse L, Roth SM, Wolfarth B, Rankinen T,
180 Bouchard C. Advances in Exercise, Fitness, and Performance Genomics in 2015. Medicine
181 and science in sports and exercise. 2016.
- 182 26. Ahmetov II, Fedotovskaya ON. Current Progress in Sports Genomics. Adv Clin
183 Chem. 2015;70:247-314.
-

Table 1. Gene variants for endurance and power/strength athlete status (Adapted from [26]).

Gene	Polymorphism	Endurance related marker	Power/ strength-related marker	Endurance		Power/Strength	
				Number of studies with positive results	Number of studies with negative or controversial results	Number of studies with positive results	Number of studies with negative or controversial results
ACE	Alu I/D (rs4646994)	I	D	16	12	7	7
ACTN3	R577X (rs1815739 C/T)	577X	Arg577	4	14	12	5
ADRB2	Gly16Arg (rs1042713 G/A) Gln27Glu (rs1042714 C/G)	16Arg -	Gly16 27Glu	2 -	1 -	1 1	- -
AGT	Met235Thr (rs699 T/C)	-	235Thr	-	-	2	-
BDKRB2	rs1799722 C/T	rs1799722 T	-	1	-	-	-
COL5A1	rs12722 C/T (BstUI)	rs12722 T	-	2	-	-	-
GABPB1 (NRF2)	rs7181866 A/G	rs7181866 G	-	2	1	-	-
IL6	-174 C/G (rs1800795 C/G)	-	rs1800795 G	-	-	2	1
PPARA	rs4253778 G/C	rs4253778 G	rs4253778 C	5	-	2	1
PPARGC1A	Gly482Ser (rs8192678 G/A)	Gly482	-	4	3	-	-
VEGFA	rs2010963 G/C	rs2010963 C	-	1	-	-	-

